Form 4: Director William Rastetter Exercises NBIX Stock Units

Neurocrine Biosciences Director William H. Rastetter acquired 3,318 shares of common stock through the vesting of restricted stock units.

Summary

• Director William H. Rastetter acquired 3,318 shares of Neurocrine Biosciences (NBIX) common stock on May 21, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on May 21, 2025.
• Following the transaction, the reporting person beneficially owns 43,678 shares held by the Rastetter Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing standard director compensation and equity vesting rather than a strategic market move.

Positives

• Director maintains a significant equity stake of 43,678 shares, aligning interests with shareholders.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that routine RSU vesting for board members is a standard component of executive and director compensation packages in the biotechnology sector, signaling normal corporate governance practices.

Comparison to Industry Standards

• The transaction follows standard equity compensation practices for directors in the mid-to-large cap biotech industry.
• The retention of shares post-vesting is consistent with long-term alignment strategies seen at peers like Vertex Pharmaceuticals or BioMarin.

Related Party Transactions

• Shares are held by the Rastetter Family Trust, of which the reporting person has voting and investment power.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• None.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Trading, Director Ownership, Restricted Stock Units